Memphasys highlights RoXsta’s diagnostic potential with key manuscript publication

Memphasys (ASX:MEM) has announced the acceptance of a key manuscript, detailing the capabilities of its RoXsta system, in the journal Antioxidants.

The advancement showcases the commercial and scientific potential of RoXsta, a diagnostic platform designed to address oxidative stress across various biological applications.

The study, co-authored by Memphasys' Scientific Director, Laureate Professor John Aitken, alongside researchers from the University of Newcastle, highlights the RoXsta system's ability to accurately profile oxidative stress in human and animal samples.

The publication emphasises RoXsta's role in addressing conditions linked to oxidative stress, including infertility, cardiovascular diseases, neurodegenerative disorders, and cancer.

David Ali, Managing Director and CEO of Memphasys, commented, "This publication is a testament to RoXsta’s transformative capabilities. Its diagnostic power not only reinforces Memphasys’ leadership in reproductive health but also positions us for broader market opportunities in livestock and clinical applications."

Memphasys is pursuing expanded commercial opportunities with RoXsta, focusing on human health diagnostics, agriculture, and global market expansion.

The company considers the publication a cornerstone of its strategic focus on innovation and leadership.

The announcement aligns with Memphasys' ongoing efforts to enhance its technological footprint and deliver cutting-edge solutions across multiple industries.

The RoXsta system exemplifies the company's commitment to advancing oxidative stress management and fertility treatments.

At the time of reporting, Memphasys' share price was $0.0080.